Loading insider details...
Beta
Latest Form 4 (Sep 30, 2026): Conversion of 3,334,938 ADRX shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 30, 2026 | ADARx Pharmaceuticals, Inc. (ADRX) | Conversion | 3,334,938 | n/a |
| May 12, 2026 | Odyssey Therapeutics, Inc. (ODTX) | Conversion | 474,048 | n/a |
| May 1, 2026 | Avalyn Pharma Inc. (AVLN) | Conversion | 1,419,298 | n/a |
| Oct 14, 2025 | Zenas BioPharma, Inc. (ZBIO) | Purchase | 63,158 | $1.20M |
| Sep 17, 2024 | Zenas BioPharma, Inc. (ZBIO) | Conversion | 1,505,388 | n/a |
| Nov 29, 2023 | eFFECTOR Therapeutics, Inc. (EFTR) | Sale | 430,578 | $261.1K |
| May 15, 2023 | Arcellx, Inc. (ACLX) | Sale | 631,932 | $28.44M |
| Dec 20, 2022 | Design Therapeutics, Inc. (DSGN) | Purchase | 500,000 | $4.14M |
| Feb 10, 2022 | Arcellx, Inc. (ACLX) | Conversion | 1,550,309 | n/a |
| Apr 1, 2021 | Design Therapeutics, Inc. (DSGN) | Conversion | 4,439,839 | n/a |